We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle

By LabMedica International staff writers
Posted on 30 Apr 2024

Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. More...

It primarily results from the inappropriate and excessive use of antibiotics, which reduces the efficacy of treatments for various infectious diseases, jeopardizing significant medical advancements and substantially inflating healthcare costs. The World Health Organization (WHO) stresses the importance of preventing infections, ensuring universal access to quality diagnostic and treatment options, and fostering innovation in surveillance and research as critical strategies to combat AMR in human health. In a significant stride towards preventing AMR, a groundbreaking medical device has been developed to accurately differentiate between viral and bacterial infections, thereby assisting doctors in administering precise and effective treatment.

Developed by Smart Blood Analytics Swiss (Zürich, Switzerland), the VIRUS vs. BACTERIA Clinical Decision Support Software utilizes just 17 routine blood parameters, biological sex, and age to effectively distinguish between viral and bacterial infections. With routine blood testing widely available globally, VIRUS vs. BACTERIA significantly enhances the ability of physicians to differentiate between viral and bacterial infections and supports the rational use of antibiotics, particularly in scenarios where traditional blood markers have limited diagnostic value.

The VIRUS vs. BACTERIA Clinical Decision Support Software has been awarded EU-MDR (European Medical Device Regulation) certification. As the healthcare sector continues to confront challenges that demand innovative responses, VIRUS vs. BACTERIA represents a promising solution. With its global availability, user-friendly interface, and robust capabilities, this advanced tool is well-positioned to empower healthcare professionals in their ongoing fight against AMR.

"This achievement shows our commitment to advancing healthcare through innovation,” said Dr. Marko Notar, CEO of Smart Blood Analytics Swiss. “By providing clinicians with a precise tool to differentiate between viral and bacterial infections, we aim to empower doctors with more information and help them in their decision of antibiotic prescriptions. This contributes to more effective healthcare practices."

Related Links:
Smart Blood Analytics Swiss


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.